alexa
Reach Us +44-176-4910199
Androgen Receptor and Hepatocellular Carcinoma | OMICS International
ISSN: 2161-069X
Journal of Gastrointestinal & Digestive System

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Androgen Receptor and Hepatocellular Carcinoma

Tatsuo Kanda1*, Osamu Yokosuka1 and Masao Omata2,3

1Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

2Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi (400-8506), Japan

3University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo (113-8655), Japan

*Corresponding Author:
Tatsuo Kanda
Associate Professor, Department of Gastroenterology and Nephrology
Chiba University, Graduate School of Medicine
1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
Tel: +81-43-226 2086
Fax: +81-432262088
E-mail: [email protected]

Received date: April 22, 2013; Accepted date: June 06, 2013; Published date: June 08, 2013

Citation: Kanda T, Yokosuka O, Omata M (2013) Androgen Receptor and Hepatocellular Carcinoma. J Gastroint Dig Syst S12:012. doi: 10.4172/2161-069X.S12-012

Copyright: © 2013 Kanda T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Gastrointestinal & Digestive System

Abstract

The androgen receptor (AR) exists in normal liver as well as in human hepatocellular carcinoma (HCC) tissues. Recent studies revealed that AR plays an important role in hepatitis B viral as well as hepatitis C viral hepatocarcinogenesis. The targeting of AR might be developed as a new therapeutic option against HCC. This article provides information regarding the association between AR and HCC.

Keywords

Androgen receptor; Foxa; HBV; HCV; STAT3; VEGF

Abbreviations

HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; HCC: Hepatocellular Carcinoma; AR: Androgen Receptor; DBD: DNA-Binding Domain; ARE: Androgen Response Element; LBD: Ligand-Binding Domain; VEGF: Vascular Endothelial Growth Factor; STAT3: Signal Transducer and Activator of Transcription-3; Foxa: Vertebrae Forkhead Box A

Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most commonly implicated risk factors of hepatocellular carcinoma (HCC) [1-3]. Irrespective of its cause, gender differences also exist in its prevalence [4].

Androgen receptor (AR), belonging to nuclear receptors, is putatively involved in the development of cancers such as prostate cancer, HCC and pancreatic cancer [5-7]. Androgen as a ligand interacts with AR, leading to a suggested link between transcriptional control and physiology. AR is characterized by a central DNA-binding domain (DBD), which targets AR to specific DNA sequences known as androgen response elements (AREs). The C-terminal half of the receptor encompasses the ligand-binding domain (LBD), which possesses the essential property of androgen recognition and ensures both specificity and selectivity of the physical response: LBD can be thought of as a molecular switch that, upon binding with ligand, shifts the receptor to a transcriptionally active state [8-10].

ARE is present in regulatory elements on target genes such as vascular endothelial growth factor (VEGF) and transforming growth factor beta-1, and regulates the growth and proliferation of hepatocytes [11,12]. Sorafenib, a molecular-targeted agent that inhibits tumor cell proliferation and angiogenesis by inhibiting Raf serine-threonine kinase (MAPKK kinase, MAPKKK), and VEGF, platelet-derived growth factor beta (PDGF), fms-related tyrosine kinase 3 (FLT3), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (C-Kit) receptor tyrosine kinase, was approved for treatment of advanced HCC in Europe, USA, Japan and other countries [13,14]. A selective transforming growth factor beta-1 receptor inhibits phosphorylation of the beta 1 integrin intracytoplasmic tail, blocking invasion of HCC cells [15].

Nagasue et al. reported that HCC had a significantly higher concentration of androgen receptors than did the surrounding liver tissue [6]. There are several reports concerning the expression of AR mRNA and AR protein in tumor and in non-tumor parts of liver, suggesting that AR plays an important role in hepatocarcinogenesis [6,16-35].

Androgen Receptor-Mediating Signaling in HCVrelated Hepatocarcinogenesis

HCV core protein, which has a size of ~20 kDa, is one of the structural proteins. It has been reported that HCV core protein is involved in hepatocarcinogenesis [36-42]. Expression of HCV core protein as well as HCV full-length protein leads to activation of the AR signaling pathway in the presence of androgen [43]. Cell culture-grown HCV infection in human hepatocytes also augments AR-mediated signaling in the presence of androgen [43,44]. These results showed that HCV core protein might cross-talk with the AR signaling pathway for promotion of carcinogenesis.

gastrointestinal-digestive-androgen-receptor

Figure 1: Mechanism of androgen receptor (AR)-mediated hepatocarcinogenesis.
HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; AR, androgen receptor; VEGF, vascular endothelial growth factor; STAT3, signal transducer and activator of transcription-3; Foxa, vertebrae forkhead box A; GSK-3ß kinase, glycogen synthase kinase-3beta kinase. Bold arrow indicates androgen response element (ARE).

Signal transducer and activator of transcription-3 (STAT3) is often constitutively phosphorylated and activated in human cancers and in transformed cell lines and is implicated in tumorigenesis [45]. HCV core increased STAT3 phosphorylation both at Ser-727 and at Tyr-705, which in turn activates AR [43]. HCV infection also enhances VEGF, one of the target genes of AR [11], and induces in vitro angiogenesis in the presence of androgen [43]. HCV core protein could be an activator of AR in the male-dominant disease HCC.

Androgen Receptor-Mediating Signaling in HBVrelated Hepatocarcinogenesis

The male predominance in HBV-related HCC is significantly high, with a ratio of 5-7:1 [4]. HBx is the only HBV nonstructural gene that functions as a multifunctional regulator modulating gene transcription, cell responses to genotoxic stress, protein degradation, apoptosis, and several signaling pathways [46-48]. HBx, which has a size of ~17 kDa, can physically bind to AR [49]. HBx-mediated enhancement of AR activity is androgen-dependent and could be mediated through indirect mechanism involving calcium and c-Src signaling pathways [50]. HBx enhances the AR transcriptional activity through two kinases: c-Src and glycogen synthase kinase-3beta kinase [51]. AR promotes HBV-induced hepatocarcinogenesis through modulation of HBV RNA transcription [52]. The androgen pathway can increase the transcription of HBV through direct binding to the ARE sites in HBV enhancer I, leading to a higher HBV titer in male carriers and increased risk of HCC [53]. These facts together suggest that the targeting of AR might be developed as a new therapeutic strategy against HBV-related HCC [54].

Ma et al. [54] reported that mice lacking hepatic AR developed later and less HCC than their wild-type littermates with comparable serum testosterone in both males and females when using the Cre-Lox conditional knockout mouse model injected with carcinogen and that AR may promote hepatocarcinogenesis via increased cellular oxidative stress and DNA damage, as well as by suppression of p53-mediated DNA damage sensing/repairing system and cell apoptosis. Recently, it has been shown that vertebrae forkhead box A (Foxa) factors and their targets estrogen receptor (ERα) and/or AR play an important role in the sexual dimorphism of HCC [55]. In conclusion, AR as well as ERα [56] could be involved in human hepatocarcinogenesis. Targeting AR might be developed as new molecular-target therapy against not only HBV-related but also HCV-related HCC.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 12579
  • [From(publication date):
    specialissue-2013 - Nov 20, 2019]
  • Breakdown by view type
  • HTML page views : 8776
  • PDF downloads : 3803
Top